Selecting the right candidate: Which disease-causing variants are eligible for N=1 ASOs?
Individualized genetic treatments provide new opportunities for targeted therapies for rare disease patients. Unfortunately, not all individuals affected by a rare disease qualify for tailored N=1 approaches, and selecting those most likely to benefit is challenging. Patient identification can be divided into the evaluation of (i) the disease-causing variant, (ii) the disease, and (iii) the status of the affected individual. DCRT's Marlen Lauffer will tell you about our efforts to identify eligible variants in the N1C seminar series on 18th September 2023.
posted on September 4, 2023
Jan Veldink (UMCU) and Peter van den Akker (UMCG) will become DCRT partners in 2026.
DCRT researchers to attend the N1C annual meeting and the OTS in Budapest in October
DCRT presentations at the 4th DATS in Groningen
Bachelor student Noortje Groenendijk joins DCRT for an internship
Keynotes, invited speakers and sponsors at DATS 2025 in Groningen
Master student Tracy Wüsthoff joins the DCRT for an internship
Come and join the DCRT at the Dutch Antisense Therapeutics Symposium in Groningen!
Master student Okke Faber joins the DCRT
DCRT's Ype Elgersma will be interviewed on television about his work on epilepsy
Happy Christmas holidays from all of us at DCRT!